The companies plan to codevelop Adaptive's ClonoSeq assay to measure minimal residual disease in ALL.
The partners will characterize patient immune response to two new investigational immunotherapies from Argos Therapeutics.
The company is using its MIRA assay internally and in research collaborations to identify biomarkers that can serve as the basis for immunotherapies.
Executives from Thermo Fisher Scientific, Qiagen, Danaher, Counsyl, Human Longevity, and Adaptive Biotechnologies provided business updates to conference goers.
An NGS-based assay was better at diagnosing CTCL than PCR-based tests, and could distinguish between malignant and benign skin lesions and identify recurrence.
The financing comes from new and existing investors and will be used to fund research and development of the firm's T cell and B cell receptor sequencing projects.
The partners will compare Adaptive Bio's clonoSeq MRD test with flow cytometry for accuracy and reliability in monitoring MRD in multiple myeloma patients.
The results need to be validated but demonstrate the clinical utility of a more sensitive screen for detecting minimal residual disease.
Adaptive hopes to develop a gold standard for immune sequencing using the combined technologies.
Adaptive Biotechnologies CEO Chad Robins will remain as CEO, and Sequenta CEO Tom Willis and CSO Malek Faham will join the senior leadership team.
Startup companies are taking on personalized medicine, CNET reports.
Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.
The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.
In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.